Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI939 in advanced malignant tumors
NCT04353830Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- May 2020
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of tamgiblimab in advanced malignant solid tumor (3 arms), sponsored by Innovent Biologics. Primary endpoints: Number of subjects with Adverse Events and Serious Adverse Events up to 2 years and Percentage of Participants with Dose-Limiting Toxicities. Started May 2020; status: completed.
02
Drugs
tamgiblimab
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT04353830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04353830.